Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.
about
Signs of deferasirox genotoxicityThe role of Dickkopf-3 overexpression in esophageal adenocarcinomaLow oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells.A comparative study of the iron status of patients with oesophageal adenocarcinoma to determine suitability for a clinical trial of iron chelation therapy.Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.A novel intraperitoneal metastatic xenograft mouse model for survival outcome assessment of esophageal adenocarcinomaTargeting cancer by binding iron: Dissecting cellular signaling pathwaysRegulators of Iron Homeostasis: New Players in Metabolism, Cell Death, and Disease.Iron chelation: a potential therapeutic strategy in oesophageal cancer.Iron deprivation in cancer--potential therapeutic implicationsEffects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma.The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.Iron chelation in the treatment of cancer: a new role for deferasirox?Two cell cycle blocks caused by iron chelation of neuroblastoma cells: separating cell cycle events associated with each block.Endothelial protein C receptor is overexpressed in colorectal cancer as a result of amplification and hypomethylation of chromosome 20qThe Iron Chelator, Dp44mT, Effectively Inhibits Human Oral Squamous Cell Carcinoma Cell Growth in Vitro and in Vivo.Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.The potential of deferasirox as a novel therapeutic modality in gastric cancerAnti-leukemic properties of deferasirox via apoptosis in murine leukemia cell lines.Iron chelation: an adjuvant therapy to target metabolism, growth and survival of murine PTEN-deficient T lymphoma and human T lymphoblastic leukemia/lymphoma.Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma.Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo.A novel, nontoxic iron chelator, super-polyphenol, effectively induces apoptosis in human cancer cell lines
P2860
Q33849491-31C81989-55D1-4A24-94DC-F1078C89CF3CQ35889299-D16E8ED3-F76E-4D61-9791-B6A80FC508B6Q35911202-14DB906C-27C9-48A4-A024-67886D0C1325Q36071604-25CE788B-E8A2-46DC-A013-E30CD95CD67AQ36119319-72881479-C98E-472D-8288-721E563E969AQ36287407-8EB59759-8486-4087-A303-552FFE587C7FQ36326247-C0D5A4AF-0A61-490E-A0DC-387323C43313Q36665139-015E69CE-9485-4215-9121-8F712575C8D5Q36681739-5C644ABC-F19A-4CD4-BD31-31FBA95EA05FQ37177365-2BCA3734-7988-4E89-90EC-8B817A90EA8FQ37373290-2FE0430B-3BA4-4433-B666-7E7ED191E554Q37665665-C01E83C7-0176-4EC1-9834-EA36E0295169Q38112400-DFDF7ED5-2AC6-4A09-84CA-AD7F706BE4E5Q38568878-754F8448-307E-47F0-BA06-81EF5E1B7C74Q38695836-2AFFFED8-33BB-42C9-887A-8F4316092EA0Q38748533-399FCDFD-735B-4C50-B816-354470E67F38Q38763826-A92A4F6A-B80C-4407-83E1-0F503963B46AQ38787167-5F00F625-9E43-44D5-BED3-6382030F4F92Q38892236-893D2A46-B8D3-49FB-B8D6-525EB1F9901DQ46478520-35781983-9C84-4AA8-9E01-AFC2F9F66B96Q52688051-365CF180-00AA-497F-9EFB-8414CE798A0AQ55447773-A1858D81-41A6-4B5E-96B3-5BE22A063DDAQ58697719-31720EAC-7E61-46F2-9A8B-5A17DE6ECADE
P2860
Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Deferasirox (ICL670A) effectiv ...... r growth in vitro and in vivo.
@ast
Deferasirox (ICL670A) effectiv ...... r growth in vitro and in vivo.
@en
type
label
Deferasirox (ICL670A) effectiv ...... r growth in vitro and in vivo.
@ast
Deferasirox (ICL670A) effectiv ...... r growth in vitro and in vivo.
@en
prefLabel
Deferasirox (ICL670A) effectiv ...... r growth in vitro and in vivo.
@ast
Deferasirox (ICL670A) effectiv ...... r growth in vitro and in vivo.
@en
P2093
P2860
P356
P1476
Deferasirox (ICL670A) effectiv ...... r growth in vitro and in vivo.
@en
P2093
C Chadwick
C Tselepis
D Alderson
D B Lovejoy
D R Richardson
D S Kalinowski
P2860
P304
P356
10.1111/BPH.12045
P407
P577
2013-03-01T00:00:00Z